全文获取类型
收费全文 | 2283篇 |
免费 | 157篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 33篇 |
儿科学 | 60篇 |
妇产科学 | 48篇 |
基础医学 | 319篇 |
口腔科学 | 89篇 |
临床医学 | 224篇 |
内科学 | 400篇 |
皮肤病学 | 37篇 |
神经病学 | 222篇 |
特种医学 | 73篇 |
外科学 | 200篇 |
综合类 | 23篇 |
一般理论 | 1篇 |
预防医学 | 297篇 |
眼科学 | 67篇 |
药学 | 167篇 |
中国医学 | 9篇 |
肿瘤学 | 179篇 |
出版年
2023年 | 15篇 |
2022年 | 26篇 |
2021年 | 93篇 |
2020年 | 54篇 |
2019年 | 86篇 |
2018年 | 91篇 |
2017年 | 64篇 |
2016年 | 71篇 |
2015年 | 81篇 |
2014年 | 97篇 |
2013年 | 148篇 |
2012年 | 195篇 |
2011年 | 193篇 |
2010年 | 93篇 |
2009年 | 88篇 |
2008年 | 143篇 |
2007年 | 162篇 |
2006年 | 152篇 |
2005年 | 146篇 |
2004年 | 122篇 |
2003年 | 136篇 |
2002年 | 101篇 |
2001年 | 11篇 |
2000年 | 5篇 |
1999年 | 9篇 |
1998年 | 10篇 |
1997年 | 6篇 |
1996年 | 6篇 |
1995年 | 5篇 |
1994年 | 3篇 |
1992年 | 4篇 |
1991年 | 3篇 |
1990年 | 3篇 |
1989年 | 2篇 |
1988年 | 2篇 |
1987年 | 1篇 |
1985年 | 1篇 |
1983年 | 1篇 |
1982年 | 1篇 |
1981年 | 2篇 |
1979年 | 2篇 |
1975年 | 3篇 |
1973年 | 1篇 |
1969年 | 1篇 |
1965年 | 1篇 |
1964年 | 1篇 |
1955年 | 2篇 |
1954年 | 2篇 |
1948年 | 1篇 |
1947年 | 1篇 |
排序方式: 共有2448条查询结果,搜索用时 156 毫秒
1.
2.
Hui Yu Zhengming Chen Karla V. Ballman Mark A. Watson Ramaswamy Govindan Irena Lanc David G. Beer Raphael Bueno Lucian R. Chirieac Michael Herman Chui Guoan Chen Wilbur A. Franklin David R. Gandara Carlo Genova Kristine A. Brovsky Mary-Beth M. Joshi Daniel T. Merrick William G. Richards Fred R. Hirsch 《Journal of thoracic oncology》2019,14(1):25-36
Objectives
Anti–programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) immunotherapy has demonstrated success in the treatment of advanced NSCLC. Recently, PD-1/PD-L1 blockade also has demonstrated interesting results in small trials of neoadjuvant treatment in stage IB to IIIA NSCLC. In addition, several clinical trials using anti–PD-1/PD-L1 immunotherapy as an adjuvant or neoadjuvant treatment in patients with resectable stage NSCLC are ongoing. However, few analyses of anti–PD-1/PD-L1 immunotherapy–related biomarkers in early-stage squamous cell lung carcinoma (SqCLC) have been reported. In this study, we evaluated PD-L1 protein expression, tumor mutation burden, and expression of an immune gene signature in early-stage SqCLC, providing data for identifying the potential role for patients with anti–PD-1/PD-L1 treatment in early-stage SqCLC.Methods
A total of 255 specimens from patients with early-stage SqCLC were identified within participating centers of the Strategic Partnering to Evaluate Cancer Signatures program. PD-L1 protein expression by immunohistochemistry was evaluated by using the Dako PD-L1 22C3 pharmDx kit on the Dako Link 48 auto-stainer (Dako, Carpinteria, CA). Tumor mutation burden (TMB) was calculated on the basis of data from targeted genome sequencing. The T-effector and interferon gamma (IFN-γ) gene signature was determined from Affymetrix gene chip data (Affymetrix, Santa Clara, CA) from frozen specimens.Results
The prevalence of PD-L1 expression was 9.8% at a tumor proportion score cutoff of at least 50%. PD-L1 mRNA and programmed cell death 1 ligand 2 mRNA positively correlated with PD-L1 protein expression on tumor cells (TCs) and tumor-infiltrating immune cells. PD-L1 protein expression on tumor-infiltrating immune cells was correlated with the T-effector and IFN-γ gene signature (p < 0.001), but not with TMB. For TCs, all of these biomarkers were independent of each other and neither PD-L1 protein expression, TMB, or T-effector and IFN-γ gene signatures were independently prognostic for patient outcomes.Conclusions
Evaluation of PD-L1 expression, TMB, and T-effector and IFN-γ gene signatures in the cohort with early-stage SqCLC found them to be independent of each other, and none was associated with overall survival. Our results also support the hypothesis that PD-L1 expression is regulated by an intrinsic mechanism on TCs and an adaptive mechanism on immune cells. 相似文献3.
4.
5.
6.
Hugo Peyre Neha Mohanpuria Katarzyna Jednorg Stefan Heim Marion Grande Muna van Ermingen‐Marbach Irene Altarelli Karla Monzalvo Camille Michle Williams David Germanaud Roberto Toro Franck Ramus 《The European journal of neuroscience》2020,52(6):3595-3609
Despite evidence for a difference in total brain volume between dyslexic and good readers, no previous neuroimaging study examined differences in allometric scaling (i.e. differences in the relationship between regional and total brain volumes) between dyslexic and good readers. The present study aims to fill this gap by testing differences in allometric scaling and regional brain volume differences in dyslexic and good readers. Object‐based morphometry analysis was used to determine grey and white matter volumes of the four lobes, the cerebellum and limbic structures in 130 dyslexic and 106 good readers aged 8–14 years. Data were collected across three countries (France, Poland and Germany). Three methodological approaches were used as follows: principal component analysis (PCA), linear regression and multiple‐group confirmatory factor analysis (MGCFA). Difference in total brain volume between good and dyslexic readers was Cohen's d = 0.39. We found no difference in allometric scaling, nor in regional brain volume between dyslexic and good readers. Results of our three methodological approaches (PCA, linear regression and MGCFA) were consistent. This study provides evidence for total brain volume differences between dyslexic and control children, but no evidence for differences in the volumes of the four lobes, the cerebellum or limbic structures, once allometry is taken into account. It also finds no evidence for a difference in allometric relationships between the groups. We highlight the methodological interest of the MGCFA approach to investigate such research issues. 相似文献
7.
8.
Karla González Suitt Cynthia Franklin Rayen Cornejo Yessenia Castro Sara Smock Jordan 《Journal of ethnicity in substance abuse》2019,18(1):103-128
Solution-focused brief therapy (SFBT) is a resource-based, future-oriented therapeutic approach that focuses on finding exceptions to problems and identifying coping strategies to build solutions. SFBT has been efficacious with individuals with alcohol use disorders. Chile experiences high levels of alcohol consumption and alcohol-related health consequences. Despite the international dissemination of SFBT, this is the first study to attempt a linguistic adaptation of SFBT in a Latin American country. We conducted 9 cognitive interviews to examine 13 translated main SFBT tools and 3 focus groups to gather information on cultural aspects of alcohol use in primary care. Results suggest that Chileans understood most SFBT tools, albeit with some linguistic modifications of original translations, and that family, gender, and meaningful issues should be considered when working with individuals with alcohol use disorders. 相似文献
9.
Jenny G. Turcott Eva Juárez-Hernández Martha De la Torre-Vallejo Karla Sánchez-Lara Julissa Luvian-Morales 《Nutrition and cancer》2016,68(2):241-249
We evaluated the effects of cisplatin and paclitaxel on taste acuity and their associations with nutritional and health-related quality of life (HRQL) in patients with advanced non-small-cell lung cancer (NSCLC). Forty chemotherapy (CT)-naïve patients were assessed at baseline and after two cycles of paclitaxel and cisplatin. The taste evaluation was performed using a rinsing technique to identify detection and recognition thresholds (DT and RT) of bitter, sweet, and umami tastes. At baseline, 37.5% of the patients reported dysgeusia. After CT, the patients showed lower medians DT (p = 0.017) and RT (p = 0.028) for umami taste. These decreases were associated with clinical neuropathy, worse HRQL, and a tendency toward increased appetite loss. Additionally, CT did not significantly reduce the median DT for sweet (p = 0.09), which is associated with lower intake of protein (p = 0.015), animal protein (p = 0.010), fat (p = 0.004), and iron (p = 0.047). CT decreased the median DT for bitter (p = 0.035); however, this decrease was not associated with nutritional parameters or with HRQL. Sensitivity to taste increased with paclitaxel and cisplatin CT, making foods more unpleasant, and it was associated with neuropathy, worse HRQL, and reduced nutrient intake in advanced NSCLC patients. The protocol was registered at clinicaltrials.gov (NCT01540045). 相似文献
10.